XNASONCO
Market cap6mUSD
Dec 26, Last price
0.35USD
1D
2.94%
1Q
-94.13%
IPO
-99.39%
Name
Blue Water Biotech Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-13m
L+288.91%
CFO
-9m
L+325.53%
Profile
Blue Water Vaccines, Inc., a biotechnology company, engages in the research and development of vaccines to prevent infectious diseases worldwide. The company's lead vaccine programs that are under preclinical development include BWV-101, an influenza vaccine; and BWV-102, a H1 pre-pandemic vaccine. It also has other pipeline under preclinical development comprising BWV-201, a streptococcus pneumoniae induced acute otitis media vaccine program; BWV-301, a norovirus-rotavirus vaccine program; and BWV-302, a norovirus-malaria vaccine program. The company was incorporated in 2018 and is based in Cincinnati, Ohio.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY |
|---|---|---|---|---|
| 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||
Revenues | ||||
Cost of revenue | 13,481 | 3,417 | ||
Unusual Expense (Income) | ||||
NOPBT | (13,481) | (3,417) | ||
NOPBT Margin | ||||
Operating Taxes | (130) | |||
Tax Rate | ||||
NOPAT | (13,352) | (3,417) | ||
Net income | (13,290) 288.91% | (3,417) 116.72% | ||
Dividends | ||||
Dividend yield | ||||
Proceeds from repurchase of equity | 34,301 | |||
BB yield | -254.11% | |||
| Debt | ||||
Debt current | ||||
Long-term debt | ||||
Deferred revenue | ||||
Other long-term liabilities | 1,499 | |||
Net debt | (25,753) | (1,928) | ||
| Cash flow | ||||
Cash from operating activities | (8,699) | (2,044) | ||
CAPEX | (9) | (2) | ||
Cash from investing activities | (9) | (2) | ||
Cash from financing activities | 32,532 | (334) | ||
FCF | (13,354) | (3,194) | ||
| Balance | ||||
Cash | 25,753 | 1,928 | ||
Long term investments | ||||
Excess cash | 25,753 | 1,928 | ||
Stockholders' equity | (19,376) | (5,957) | ||
Invested Capital | 41,587 | 7,403 | ||
ROIC | ||||
ROCE | ||||
| EV | ||||
Common stock shares outstanding | 12,271 | 10,914 | ||
Price | 1.10 | |||
Market cap | 13,499 | |||
EV | (12,254) | |||
EBITDA | (13,474) | (3,412) | ||
EV/EBITDA | 0.91 | |||
Interest | 61 | |||
Interest/NOPBT | ||||